IP Library › Patent Application 11584832
Patent Application
App. No. 11/584,832

Glycolated and glycosylated poultry derived therapeutic proteins

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
11/584,832
Abstract

Compositions containing a glycosylated therapeutic amino acid sequence obtained from a transgenic avian wherein the therapeutic amino acid sequence is a glycoprotein and includes a covalently bonded glycol polymer.

Claims (20)

1 . A composition containing a glycosylated therapeutic amino acid sequence obtained from a transgenic avian wherein the therapeutic amino acid sequence is a glycoprotein and comprises a covalently bonded glycol polymer.

2 . The composition of claim 1 wherein the avian is a chicken.

3 . The composition of claim 1 wherein the therapeutic amino acid sequence is an exogenous amino acid sequence.

4 . The composition of claim 1 wherein the therapeutic amino acid sequence is an amino acid sequence endogenous to a human.

5 . The composition of claim 1 wherein the therapeutic amino acid sequence is cytokine.

6 . The composition of claim 1 wherein the therapeutic amino acid sequence is selected from the group consisting of granulocyte colony stimulating factor, interferon alpha, interferon beta, erythropoietin and granulocyte macrophage colony stimulating factor.

7 . The composition of claim 6 wherein the therapeutic amino acid sequence is an amino acid sequence endogenous to a human.

8 . The composition of claim 6 wherein the therapeutic amino acid sequence is an antibody.

9 . The composition of claim 1 wherein the glycosylation is provided by an oviduct cell of the transgenic avian.

10 . The composition of claim 9 wherein the oviduct cell is a tubular gland cell.

11 . The composition of claim 1 wherein the therapeutic amino acid sequence is O-glycosylated.

12 . The composition of claim 1 wherein the therapeutic amino acid sequence is N-glycosylated.

13 . The composition of claim 1 wherein the glycol polymer is a polyalkylene glycol.

14 . The composition of claim 1 wherein the glycol polymer is a polyethylene glycol.

15 . The composition of claim 1 wherein the glycol polymer is a polypropylene glycol.

16 . The composition of claim 1 wherein the glycol polymer has a molecular weight of about 300 to about 200,000.

17 . The composition of claim 1 wherein the glycol polymer is covalently bonded to an amino group of the therapeutic amino acid sequence.

18 . The composition of claim 1 wherein the glycol polymer is covalently bonded to a carboxyl group of the therapeutic amino acid sequence.

19 . A composition containing a glycosylated therapeutic amino acid sequence obtained from a transgenic avian wherein the therapeutic amino acid sequence is a glycoprotein and comprises a glycol polymer covalently bonded to a glycosylation of the therapeutic amino acid sequence.

20 . A composition containing a glycosylated therapeutic amino acid sequence obtained from a transgenic chicken wherein the therapeutic amino acid sequence is a glycoprotein and comprises a covalently bonded glycol polymer.

Assignments (2)
CHANGE OF NAME Recorded Jan 30, 2009
From: AVIGENICS, INC.
To: SYNAGEVA BIOPHARMA CORP.
Reel/Frame 022177/0940 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 23, 2006
From: YESLAND, KYLE D.
To: AVIGENICS
Reel/Frame 018455/0638 →